Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somatropin in children with IUGR
NCT00184691Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 1999
- Primary completion
- Jun 2005
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatropin in Intrauterine Growth Restriction (IUGR), sponsored by Novo Nordisk. Primary endpoints: Height Standard Deviation Score for chronological age at 48 months, Bone maturation and 1 more. Started Apr 1999; status: completed.
02
Drugs
somatropin
03
Conditions
Intrauterine Growth Restriction (IUGR)
Beyond the preview
Go deeper on NCT00184691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00184691.